Table 1. Overview of subjects, FcγR... | American Society of Hematology

Table 1.

Overview of subjects, FcγR polymorphism, clinical data, and results

Subject no. and dose of anti-RhD immune globulin, (administration route)	FcγRIIA	FcγRIIIA	FcγRIIIB	Rescue, d	RhD⁺ RBC t_1/2, h	Anti-D after 3 mo	Anti-D after 6 mo
Rhophylac, 1500 IU/300 μg (IV)
101	RR	FF	NA1NA2	-	1.59	Weak	Neg
102	ND	ND	ND	-	1.39	Aggl^*	Neg
103	HH	VF	NA2NA2	-	2.26	Aggl^*	Neg
104	HH	FF	NA1NA2	-	0.90	Neg	Neg
105	RR	FF	NA1NA2	-	3.47	Neg	Neg
106	RR	VF	NA1NA2	-	0.72	Neg	Neg
107	HH	VF	NA1NA2	-	0.91	Pos	Neg
108	ND	ND	ND	-	0.93	Neg	Neg
109	HR	VF	NA2NA2	-	0.98	Pos	Neg
MonoRho, 300 μg (IV)
201	HR	FF	NA1NA1	-	7.45	Neg	Neg
202	HR	FF	NA1NA1	7	17.33	Pos	Neg
211	RR	FF	NA2NA2	-	15.25	Neg	Neg
212	HR	FF	NA1NA2	-	6.31	Neg	Neg
MonoRho, 600 μg (IV)
301	RR	FF	NA2NA2	7	55.64	Pos	Neg
302	RR	VF	NA1NA2	7	37.46	Pos	Neg
303	HR	VF	NA2NA2	-	5.23	Neg	Neg
311	RR	FF	NA2NA2	-	78.52	Neg	Neg
312	HR	VF	NA2NA2	-	2.95	Neg	Neg
313	HR	FF	NA1NA1	-	31.22	Neg	Neg
MonoRho, 900 μg (IV)
401	ND	ND	ND	-	4.25	Neg	Neg
402	RR	VF	NA1NA2	-	5.82	Neg	Neg
403	HR	VF	NA2NA2	-	6.13	Neg	Neg
404	HH	VV	NA2NA2	-	2.01	Neg	Neg
405	ND	ND	ND	-	2.87	Neg	Neg
406	HH	VV	NA1NA2	-	4.83	Neg	Neg
MonoRho, 1200 μg (IV)
501	HR	FF	NA2NA2	7	16.33	Pos	Neg
502	HR	VF	NA1NA2	7	14.33	Pos	Neg
503	RR	FF	NA1NA2	7	21.64	Aggl^*	Neg
MonoRho, 1800 μg (IV)
1101	RR	FF	NA1NA2	11	203.35	Pos	Neg
1102	RR	VF	NA1NA2	-	9.00	Pos	Neg
1103	HH	VF	NA1NA2	-	2.26	Neg	Neg
1104	HH	VF	NA1NA2	-	4.38	Neg	Neg
1105	HR	VF	NA2NA2	-	44.55	Neg	Neg
1106	HH	FF	NA1NA2	-	29.12	Aggl^*	Neg
Rhophylac, 1500 IU (IM)
601	HH	VV	NA1NA2	-	4.91	Aggl^*	Neg
602	HR	FF	NA1NA2	-	30.15	Pos	Neg
603	HH	VV	NA2NA2	-	5.98	Weak	Neg
604	HR	VF	NA2NA2	-	7.88	Pos	Neg
605	RR	FF	NA2NA2	-	15.24	Neg	Neg
606	HR	FF	NA1NA1	-	9.55	Neg	Neg
MonoRho, 1200 μg (IM)
1001	HH	VF	NA1NA2	-	8.65	Pos	Neg
1002	HR	FF	NA1NA2	-	23.61	Aggl^*	Neg
1003	HH	VF	NA1NA2	-	25.33	Neg	Neg
1004	HH	FF	NA1NA1	-	36.13	Pos	Neg
1005	RR	FF	NA1NA2	-	50.28	Neg	Neg
1006	RR	FF	NA1NA2	-	131.43	Neg	Neg

Subject no. and dose of anti-RhD immune globulin, (administration route)	FcγRIIA	FcγRIIIA	FcγRIIIB	Rescue, d	RhD⁺ RBC t_1/2, h	Anti-D after 3 mo	Anti-D after 6 mo
Rhophylac, 1500 IU/300 μg (IV)
101	RR	FF	NA1NA2	-	1.59	Weak	Neg
102	ND	ND	ND	-	1.39	Aggl^*	Neg
103	HH	VF	NA2NA2	-	2.26	Aggl^*	Neg
104	HH	FF	NA1NA2	-	0.90	Neg	Neg
105	RR	FF	NA1NA2	-	3.47	Neg	Neg
106	RR	VF	NA1NA2	-	0.72	Neg	Neg
107	HH	VF	NA1NA2	-	0.91	Pos	Neg
108	ND	ND	ND	-	0.93	Neg	Neg
109	HR	VF	NA2NA2	-	0.98	Pos	Neg
MonoRho, 300 μg (IV)
201	HR	FF	NA1NA1	-	7.45	Neg	Neg
202	HR	FF	NA1NA1	7	17.33	Pos	Neg
211	RR	FF	NA2NA2	-	15.25	Neg	Neg
212	HR	FF	NA1NA2	-	6.31	Neg	Neg
MonoRho, 600 μg (IV)
301	RR	FF	NA2NA2	7	55.64	Pos	Neg
302	RR	VF	NA1NA2	7	37.46	Pos	Neg
303	HR	VF	NA2NA2	-	5.23	Neg	Neg
311	RR	FF	NA2NA2	-	78.52	Neg	Neg
312	HR	VF	NA2NA2	-	2.95	Neg	Neg
313	HR	FF	NA1NA1	-	31.22	Neg	Neg
MonoRho, 900 μg (IV)
401	ND	ND	ND	-	4.25	Neg	Neg
402	RR	VF	NA1NA2	-	5.82	Neg	Neg
403	HR	VF	NA2NA2	-	6.13	Neg	Neg
404	HH	VV	NA2NA2	-	2.01	Neg	Neg
405	ND	ND	ND	-	2.87	Neg	Neg
406	HH	VV	NA1NA2	-	4.83	Neg	Neg
MonoRho, 1200 μg (IV)
501	HR	FF	NA2NA2	7	16.33	Pos	Neg
502	HR	VF	NA1NA2	7	14.33	Pos	Neg
503	RR	FF	NA1NA2	7	21.64	Aggl^*	Neg
MonoRho, 1800 μg (IV)
1101	RR	FF	NA1NA2	11	203.35	Pos	Neg
1102	RR	VF	NA1NA2	-	9.00	Pos	Neg
1103	HH	VF	NA1NA2	-	2.26	Neg	Neg
1104	HH	VF	NA1NA2	-	4.38	Neg	Neg
1105	HR	VF	NA2NA2	-	44.55	Neg	Neg
1106	HH	FF	NA1NA2	-	29.12	Aggl^*	Neg
Rhophylac, 1500 IU (IM)
601	HH	VV	NA1NA2	-	4.91	Aggl^*	Neg
602	HR	FF	NA1NA2	-	30.15	Pos	Neg
603	HH	VV	NA2NA2	-	5.98	Weak	Neg
604	HR	VF	NA2NA2	-	7.88	Pos	Neg
605	RR	FF	NA2NA2	-	15.24	Neg	Neg
606	HR	FF	NA1NA1	-	9.55	Neg	Neg
MonoRho, 1200 μg (IM)
1001	HH	VF	NA1NA2	-	8.65	Pos	Neg
1002	HR	FF	NA1NA2	-	23.61	Aggl^*	Neg
1003	HH	VF	NA1NA2	-	25.33	Neg	Neg
1004	HH	FF	NA1NA1	-	36.13	Pos	Neg
1005	RR	FF	NA1NA2	-	50.28	Neg	Neg
1006	RR	FF	NA1NA2	-	131.43	Neg	Neg

IV indicates intravenously; -, not required; Neg, negative; ND, not done; Aggl, agglutination; Pos, positive; and IM, intramuscularly.

Blood was tested with a panel of 11 test RBC types. Some of them showed a very weak agglutination, but a specific antibody could not be identified. Agglutination was scored by visual assessment from ++++ (strong agglutination) descending to - (no agglutination) as defined by the DiaMed ID gel scale. The positive agglutination was rated as a 1+ reaction on the ID gel scale

View Large

This Feature Is Available To Subscribers Only